Arbutus to Participate in Three Upcoming Investor Conferences

On February 6, 2023 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences (Press release, Arbutus Biopharma, FEB 6, 2023, View Source [SID1234626856]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Securities Global Biopharma Conference – Virtual: February 14-16, 2023

Cowen 43rd Annual Health Care Conference: Formal Presentation at 1:30 pm ET on March 7, 2023

Jefferies Biotech on the Bay Summit: March 16-17, 2023

To access the live webcast of the presentation for the Cowen 43rd Annual Health Care Conference please visit: View Source An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.